Author:
Derendinger Brigitta,Dippenaar Anzaan,de Vos Margaretha,Huo Stella,Alberts Rencia,Tadokera Rebecca,Limberis Jason,Sirgel Frik,Dolby Tania,Spies Claudia,Reuter Anja,Folkerts Megan,Allender Christopher,Lemmer Darrin,Van Rie Annelies,Gagneux Sebastien,Rigouts Leen,te Riele Julian,Dheda Keertan,Engelthaler David M,Warren Robin,Metcalfe John,Cox Helen,Theron Grant
Subject
Virology,Infectious Diseases,Microbiology (medical),Microbiology
Reference30 articles.
1. Costs to health services and the patient of treating tuberculosis: a systematic literature review;Laurence;Pharmacoeconomics,2015
2. Clinical access to bedaquiline programme for the treatment of drug-resistant tuberculosis;Conradie;Afr Med J,2014
3. WHO consolidated guidelines on drug-resistant tuberculosis treatment 2019,2020
4. A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic;Klopper;BCM Med,2020
5. Detection of a bedaquiline/clofazimine resistance reservoir in Mycobacterium tuberculosis predating the antibiotic era;van Dorp;bioRxiv,2023
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility;2024-09-04
2. Candidate anti-tuberculosis medicines and regimens under clinical evaluation;Clinical Microbiology and Infection;2024-09
3. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience;The Lancet Infectious Diseases;2024-09
4. Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility;2024-08-05
5. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance;Emerging Infectious Diseases;2024-08